Kodiak Sciences Announces Positive Trial Results for Zancuda in Wet AMD

Key Facts

Kodiak Sciences announced that its drug Zancuda met the primary endpoint in a clinical trial for the treatment of wet age-related macular degeneration. Investing.com reported that the drug, also known as tarcocimab tedromer, successfully achieved its primary efficacy targets among patients in the study.

The positive top-line results demonstrate the drug's efficacy in improving or maintaining vision, marking a significant regulatory milestone for the biotech company. These clinical developments serve as a primary catalyst for the issuer.